Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891874684> ?p ?o ?g. }
- W2891874684 endingPage "333" @default.
- W2891874684 startingPage "325" @default.
- W2891874684 abstract "Immune checkpoint inhibitors are drugs that inhibit the “checkpoint molecules”. Different types of cancer immune checkpoint inhibitors have been approved recently: CTLA-4 monoclonal antibodies (as ipilimumab); anti-PD-1 monoclonal antibodies (as pembrolizumab and nivolumab); and anti-PD-L1 monoclonal antibodies (as atezolizumab, avelumab, and durmalumab). The increased immune response induced by these agents leads to immune-related adverse events (irAEs), that can vary from mild to fatal, according to the organ system and severity. Immune-related endocrine toxicities are thyroid dysfunctions, hypophysitis, adrenal insufficiency, and type 1 diabetes mellitus, and are usually irreversible in 50%. In particular, hypophysitis is the most frequent anti-CTLA-4-antibodies-related irAE, while thyroid abnormalities (as hypothyroidism, thyrotoxicosis, painless thyroiditis, or even “thyroid storm”) are more frequently associated with anti-PD-1-antibodies. The combination of anti-CTLA-4-antibodies, with anti-PD-1-antibodies, is associated with about 30% of irAEs. Clinical signs and symptoms vary according to the influenced target organ. Endocrinopathies can often be managed by the treating oncologist. However in more severe cases (i.e. in the presence of insulin-dependent diabetes, adrenal insufficiency, or disorders of gonadal hormones, or severe hyperthyroidism, or hypothyroidism, or long-lasting management of hypophysitis) an endocrinological evaluation, and a prompt therapy, are needed." @default.
- W2891874684 created "2018-09-27" @default.
- W2891874684 creator A5017117747 @default.
- W2891874684 creator A5018248410 @default.
- W2891874684 creator A5029781925 @default.
- W2891874684 creator A5038828476 @default.
- W2891874684 creator A5057155509 @default.
- W2891874684 creator A5057709126 @default.
- W2891874684 date "2018-09-21" @default.
- W2891874684 modified "2023-10-02" @default.
- W2891874684 title "Thyroid disorders induced by checkpoint inhibitors" @default.
- W2891874684 cites W1494696914 @default.
- W2891874684 cites W1508871122 @default.
- W2891874684 cites W1569800470 @default.
- W2891874684 cites W1605630196 @default.
- W2891874684 cites W1625861559 @default.
- W2891874684 cites W1725918626 @default.
- W2891874684 cites W1914776013 @default.
- W2891874684 cites W1967084952 @default.
- W2891874684 cites W1979651049 @default.
- W2891874684 cites W1988822265 @default.
- W2891874684 cites W1990675339 @default.
- W2891874684 cites W2005576578 @default.
- W2891874684 cites W2006041373 @default.
- W2891874684 cites W2022073464 @default.
- W2891874684 cites W2032060513 @default.
- W2891874684 cites W2036195858 @default.
- W2891874684 cites W2040851929 @default.
- W2891874684 cites W2044363258 @default.
- W2891874684 cites W2048296690 @default.
- W2891874684 cites W2070825440 @default.
- W2891874684 cites W2078616035 @default.
- W2891874684 cites W2083738283 @default.
- W2891874684 cites W2097995306 @default.
- W2891874684 cites W2104430075 @default.
- W2891874684 cites W2107484016 @default.
- W2891874684 cites W2109274792 @default.
- W2891874684 cites W2109465910 @default.
- W2891874684 cites W2109653150 @default.
- W2891874684 cites W2110773108 @default.
- W2891874684 cites W2124463063 @default.
- W2891874684 cites W2127446775 @default.
- W2891874684 cites W2137631342 @default.
- W2891874684 cites W2139503156 @default.
- W2891874684 cites W2142506385 @default.
- W2891874684 cites W2145308813 @default.
- W2891874684 cites W2152897456 @default.
- W2891874684 cites W2155995527 @default.
- W2891874684 cites W2156253417 @default.
- W2891874684 cites W2160262071 @default.
- W2891874684 cites W2161550811 @default.
- W2891874684 cites W2164433065 @default.
- W2891874684 cites W2164918836 @default.
- W2891874684 cites W2166107256 @default.
- W2891874684 cites W2166662937 @default.
- W2891874684 cites W2166667372 @default.
- W2891874684 cites W2167255026 @default.
- W2891874684 cites W2168859390 @default.
- W2891874684 cites W2177405394 @default.
- W2891874684 cites W2253549412 @default.
- W2891874684 cites W2259730793 @default.
- W2891874684 cites W2289841322 @default.
- W2891874684 cites W2305396859 @default.
- W2891874684 cites W2428806539 @default.
- W2891874684 cites W2466451466 @default.
- W2891874684 cites W2519279652 @default.
- W2891874684 cites W2560367415 @default.
- W2891874684 cites W2561156916 @default.
- W2891874684 cites W2569039074 @default.
- W2891874684 cites W2572174216 @default.
- W2891874684 cites W2577007969 @default.
- W2891874684 cites W2606361632 @default.
- W2891874684 cites W2625574648 @default.
- W2891874684 cites W2635292439 @default.
- W2891874684 cites W2744067212 @default.
- W2891874684 cites W2768429453 @default.
- W2891874684 cites W2769908638 @default.
- W2891874684 cites W2772875902 @default.
- W2891874684 cites W2782172222 @default.
- W2891874684 cites W2786816161 @default.
- W2891874684 cites W2790602098 @default.
- W2891874684 cites W2803681833 @default.
- W2891874684 cites W2924070172 @default.
- W2891874684 cites W2969153079 @default.
- W2891874684 cites W874828184 @default.
- W2891874684 doi "https://doi.org/10.1007/s11154-018-9463-2" @default.
- W2891874684 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30242549" @default.
- W2891874684 hasPublicationYear "2018" @default.
- W2891874684 type Work @default.
- W2891874684 sameAs 2891874684 @default.
- W2891874684 citedByCount "80" @default.
- W2891874684 countsByYear W28918746842018 @default.
- W2891874684 countsByYear W28918746842019 @default.
- W2891874684 countsByYear W28918746842020 @default.
- W2891874684 countsByYear W28918746842021 @default.
- W2891874684 countsByYear W28918746842022 @default.
- W2891874684 countsByYear W28918746842023 @default.
- W2891874684 crossrefType "journal-article" @default.